vasopharm GmbH

The NOSTRA III study of Germany’s Vasopharm GmbH ’s inducible nitric oxide synthase inhibitor ronopterin (VAS203) has missed its primary endpoint in patients with traumatic brain injury (TBI), but th

Revolution Medicines Inc. has been on a roll during the past year after entering into a partnership with Sanofi to develop its SHP2 inhibitor, buying Warp Drive Bio Inc. to bolster its cancer dru

vasopharm GMBH , a small German pharma company, has big decisions ahead about its possible transition from a clinical-stage to commercial company. However, everything rides on the Phase III performanc

A new biotech established by Fortress Biotech Inc. will work to produce therapeutic advances in traumatic brain injury by reducing pro-inflammatory cytokines with a pair of stem cell therapy candi